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Abstract Recently, prediction models for type 2 diabetes
mellitus (T2DM) in older adults (aged C55 year) were
developed in the KORA S4/F4 study, Augsburg, Germany.
We aimed to externally validate the KORA models in a
Dutch population. We used data on both older adults
(n = 2,050; aged C55 year) and total non-diabetic popu-
lation (n = 6,317; aged 28–75 year) for this validation. We
assessed performance of base model (model 1: age, sex,
BMI, smoking, parental diabetes and hypertension) and two
clinical models: model 1 plus fasting glucose (model 2); and
model 2 plus uric acid (model 3). For 7-year risk of T2DM,
we calculated C-statistic, Hosmer–Lemeshow v2-statistic,
and integrated discrimination improvement (IDI) as mea-
sures of discrimination, calibration and reclassification,
respectively. After a median follow-up of 7.7 years, 199
(9.7%) and 374 (5.9%) incident cases of T2DM were
ascertained in the older and total population, respectively.
In the older adults, C-statistic was 0.66 for model 1. This
was improved for model 2 and model 3 (C-statistic = 0.81)
with significant IDI. In the total population, these respective
C-statistics were 0.77, 0.85 and 0.85. All models showed
poor calibration (P \ 0.001). After adjustment for the
intercept and slope of each model, we observed good cali-
bration for most models in both older and total populations.
We validated the KORA clinical models for prediction of
T2DM in an older Dutch population, with discrimination
similar to the development cohort. However, the models
need to be corrected for intercept and slope to acquire good
calibration for application in a different setting.
Keywords Type 2 diabetes  Prediction model  External
validation  Update  Older adults
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Introduction
Type 2 diabetes is one of the major concerns in public
health, becoming more prevalent worldwide in parallel with
increasing rate of obesity and ageing [1]. There is evidence
suggesting that diabetes can be prevented by diet and life-
style modifications [2]. For this, individuals at risk of
developing diabetes need to be accurately identified [3, 4].
In the rapidly growing group of older subjects, prediction
and primary prevention of chronic complex diseases such as
diabetes are important to aid in healthy aging [5].
Risk for development of diabetes is appreciably higher
in older subjects than in younger subjects. Several pre-
diction models, including the Finnish (FINDRISC), the
Atherosclerosis Risk in Communities (ARIC), the Fra-
mingham, Data from the Epidemiological Study on the
Insulin Resistance Syndrome (DESIR) and Cambridge
diabetes risk scores, have been developed in middle-aged
populations and validated in other populations [4, 6–11].
As there are indications of ‘reverse epidemiology’ in older
populations [12, 13], it is questionable whether risk scores
developed in middle-aged populations can be extrapolated
to older subjects. Moreover, it has been shown that pre-
dictive value of common risk factors declines with ageing
[14]. Recently, the Cooperative Health Research in the
Region of Augsburg (KORA) S4/F4 models have been
developed to specifically predict the risk of type 2 diabetes
in older subjects [15]. Because some risk scores that
showed less performance when external validation was
attempted, it is important that risk scores are validated in an
independent population before they are brought into clini-
cal practice [15, 16].
Therefore, we aimed to investigate the performance of
the KORA models to predict incident type 2 diabetes in a
large sample of non-diabetic Dutch adults, in particular
older adults. We assessed performance of the model in
terms of discrimination, calibration, recalibration and
reclassification.
Methods
Population and design of the derivation study
The KORA S4/F4 study is a community-based cohort of
2,656 individuals (aged 55–74 years) living in the area of
Augsburg, Germany in 1999. Details of the study design,
recruitment, and procedures have been published elsewhere
[17]. Among 887 individuals who participated for a median
follow-up of 7-years, 91 (10.5%) incident cases of type 2
diabetes were observed in the KORA cohort [15, 17]. The
KORA data set was used to compare baseline character-
istics with those of the validation cohort.
Population and design of the validation study
We used data from the Prevention of Renal and Vascular
Endstage Disease (PREVEND) study. The PREVEND
study is a community-based prospective cohort of 8,592
inhabitants (aged 28–75 years) of the city of Groningen,
The Netherlands who were screened for baseline mea-
surements between 1997 and 1998. Details of the study
design, recruitment, and measurements have been pub-
lished elsewhere [18]. From the baseline cohort, we
excluded 295 participants who had diabetes and 1,980 with
missing data on clinical characteristics or data on follow-
up, leaving 6,317 non-diabetic total population and a
sample of 2,050 older adults (aged C55 years old) for this
prospective validation analysis. The latter was used for
primary validation while the former was used for second-
ary validation in a population with a much larger age range.
All participants gave written informed consent prior to
study inclusion. The PREVEND cohort complied with the
Declaration of Helsinki and was approved by the medical
ethics committee in The Netherlands.
Outcome, predictors and measurements
The main outcome was incidence of type 2 diabetes which
was classified if one or more of the following criteria were
met: fasting plasma glucose C7.0 mmol/l (126 mg/dl);
non-fasting sample plasma glucose C11.1 mmol/l
(200 mg/dl); self-report of a physician diagnosis of type 2
diabetes; pharmacy-registered use of glucose-lowering
agents [19]. To estimate the predicted 7-year risk for type 2
diabetes in our cohort, we calculated the linear predictors
of the KORA prediction models [15]. The base model
(model 1) included data on age, sex, parental diabetes,
body mass index (BMI), smoking status and hypertension.
The clinical KORA models included additional data on
fasting glucose, serum uric acid and HbA1c [15]. As data
on HbA1c was unavailable, we validated a reported clinical
model with data on fasting glucose (model 2) [15]. More-
over, the authors were asked to provide a clinical model
with data on fasting glucose and uric acid (model 3), pre-
sented in Supplementary Table 1.
Data analysis
To externally validate these models, we assessed the dis-
crimination and calibration performances in our cohort
[20]. The discrimination performance denotes to what
extent the model distinguishes between individuals with
and without the outcome. Discrimination was expressed as
the C-statistic with 95% confidence interval, where a value
of 1 implies a perfect discrimination and a value of 0.5
implies performance no better than chance. We compared
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the C-statistics of the clinical models to that of the base
model as reference. The calibration compares predicted
risks with observed risks. We applied the Hosmer–Leme-
show v2 test to evaluate the calibration performance. A
lower v2 value with a non-significant P value represents
good calibration. Also, calibration was visually checked by
comparing the predicted probabilities versus observed
incident cases of diabetes in each decile of predictions [20].
To recalibrate the prediction models, we used the original
KORA models and applied logistic regression to derive the
intercept and the calibration slope of each model in the
total and older populations, and separately for women and
men (Supplementary method part 1) [21]. We used these
intercepts and slopes by fitting a model with the original
linear predictor as the only covariate in the PREVEND data
set. We multiplied each linear predictor by the calibration
slope and added the calibration intercept to each original
model [21]. Thereafter, we added data on waist circum-
ference, a non-invasive risk factor for diabetes [11], to the
re-calibrated models and assessed if this could improve
predictive ability. We examined improvement of diabetes
prediction in terms of discrimination, calibration and
integrated discrimination improvement (IDI), a measure of
reclassification (Supplementary method part 2) [20]. The
analyses were performed separately in the older adults and
in total PREVEND population. All the statistical analyses
were carried out using Statistical Package for Social Sci-
ences version 18 (SPSS Inc, Chicago, Illinois, USA), Stata
software version 10.0 (Stata-Corp LP, College Station, TX,
USA) and R-2.11.0 for Windows (http://cran.r-project.org/).
Results
In the older adults, we observed 199 (9.7%) incident cases of
type 2 diabetes during follow-up for a median of 7.7 years.
In the total population, we observed 374 (5.9%) cases during
this follow-up. Baseline participants’ characteristics of the
KORA and PREVEND cohorts (aged C55 years) are shown
in Supplementary Table 2. Participants of PREVEND were
more likely to be male, older, more likely to be smoker and
to have hypertension, but had lower BMI, lower parental
history of diabetes and had lower fasting glucose and serum
uric acid than participants of KORA.
Table 1 depicts the performance of the KORA models in
terms of discrimination and calibration. In the older adults, a
relatively low discriminative ability was observed for the
base model (C-statistic = 0.66), being lower than the ori-
ginal C-statistic of 0.76 [15]. This was significantly
improved for both models 2 and 3 (C-statistic = 0.81),
being comparable with the original C-statistic of 0.81 [15].
The discriminative ability was not significantly different
between these clinical models (P = 0.78). The base and
both clinical models did not show good calibration
(P \ 0.001 for 7-year risk). When we tested the perfor-
mance of each model in the total population, we observed a
better discriminative ability for the base (C-statistic of 0.77;
P \ 0.001) and both clinical models (both C-statis-
tics = 0.85; P \ 0.001). Similarly, the base and both clin-
ical models did not show good calibration (P \ 0.001 for
7-year risk) in the total population. After adjustment for the
calibration intercept and the calibration slope of each model,
good calibration was observed for the clinical models
(P [ 0.05 for 7-year risk, Table 1), but not for the base
model. Figure 1 (A, B) depicts the agreement between the
predicted 7-year risk and observed risk of type 2 diabetes in
each decile of predictions before and after recalibration. Of
note, the predictive probability of model 3 was deviated
from the ideal line in the older adults above 15% risk (Fig-
ure 1 A); indeed, the 7-year risk was underestimated for this
risk category. The IDIs were significant when we compared
the prediction performance of the clinical models to that of
the base model (P \ 0.001). In a subsequent analysis, we
stratified total population by gender. We observed that all
KORA models showed better discrimination performance in
women than in men (Table 1). Addition of waist circum-
ference improved predictive ability of the base model in the
total population (C-statistic = 0.79; P \ 0.001), but not in
the older population separately (C-statistic = 0.67;
P = 0.30). Addition of waist circumference did not improve
predictive ability of model 3, neither in the total population
(C-statistic = 0.85; P = 0.11) nor in the older population
separately (C-statistic = 0.81; P = 0.41).
Discussion
In this external validation study, we prospectively assessed
performance of the KORA models to predict the risk of
developing type 2 diabetes in an independent Dutch pop-
ulation. We found that the prediction models with clinical
data on glucose with or without uric acid performed well
and this was much better than the base model in terms of
discrimination and reclassification in the older adults.
Moreover, we observed a similar pattern but with higher
discriminative abilities in the total population. All models
showed poor calibration performance. The calibration was
good after adjustment for the intercept and the slope of
clinical models, but not for the base model.
To our best of knowledge, there are few studies that
derive and validate prediction models for of the risk of
developing type 2 diabetes in the older adults. The main
strengths of our study were including a large population-
based cohort, available data on blood sampling in each
screening visit and pharmacy registry, and applying the
latest standards of prediction research. Some limitations
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should be addressed. First, we excluded the individuals
with missing data at baseline or during follow-up. How-
ever, the baseline characteristics of excluded participants
were similar to those who were included in our analysis.
Therefore, it is less likely that this might have led to
selection bias. Moreover, both derivation and validation
data sets were gathered among Whites and our findings
need to be further evaluated in other populations.
Our findings were consistent with previous validation
studies in which performance of other prediction models
for type 2 diabetes were tested in independent populations
[22, 23]. Of note, predictive performance of models is often
decreased in the validation sample. Several differences
between derivation and validation samples might explain
this change of performance. These include differences in
healthcare systems, methods of measurement, and patients’
characteristics [22]. Our protocol to measure the predictors
and incident cases of type 2 diabetes was very comparable
with the KORA study during similar follow-up time and
period. Regardless possible differences in healthcare sys-
tems, characteristics of the participants of PREVEND were
remarkably different from the participants of KORA.
When we calculated the C-statistic as a discrimination
measure, we observed good ability (C-statistic C 0.81) of
clinical KORA models to distinguish between incident
cases of type 2 diabetes and those who remained free of
diabetes in both older and total populations. This was
comparable for both clinical models and much higher than
the base model. This cannot be explained by differences in
the incidence of type 2 diabetes, as the C-statistic is hardly
affected by different incidences of the outcome. A better
discriminative ability of KORA models in the total popu-
lation than in the older adults might be explained by a
difference in case mix between KORA and PREVEND
cohorts, less heterogeneity among the older adults of
PREVEND, effect of predictors and difference in regres-
sion coefficients of KORA models [23]. For example,
variables like age, BMI, or hypertension discriminate better
between cases and non-cases in the total population [14]
because low BMI or hypertension is more frequent in the
younger adults who develop diabetes less often.
Both base and clinical KORA models showed poor
calibration both in the older and total populations. In other
words, the mean predicted risk by the KORA models were
significantly different from the observed risk of type 2
diabetes in the PREVEND cohort. One explanation for this
is different incidence of type 2 diabetes between KORA
and PREVEND cohorts. To further assess the calibration
performance of each models, we used logistic recalibra-
tion of the original prediction models [21]. After this
adjustment, both KORA clinical models showed good
calibration.
In conclusion, addition of fasting glucose improved
performance of KORA base model in both older and total
populations in terms of discrimination and reclassification.
Further addition of uric acid did not matter much. Both
base and clinical models showed poor calibration. After
correction for the intercept and the slope, most KORA
models showed good calibration, indicating that there is
often a need to adapt prediction models before application



















































Fig. 1 Comparison between predicted risk versus observed diabetes
frequency in the PREVEND cohort according to the KORA model 3,
Model 3, included data on the base KORA model plus glucose and
uric acid for the risk prediction of diabetes in the PREVEND cohort.
A depicts calibration plots in the older adults, aged C55 years
(n = 2,050). B depicts calibration plots in the total population
(n = 6,317). The dashed line represents an ideal calibration (with
intercept 0 and slope 1); the dotted line is for the not-recalibrated
model and the solid line is after adjustment for the intercept and slope
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